Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/128328
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRequena-Méndez, Ana-
dc.contributor.authorDavies, Geraint-
dc.contributor.authorWaterhouse, David-
dc.contributor.authorArdrey, Alison-
dc.contributor.authorJave, Oswaldo-
dc.contributor.authorLlanet López-Romero, Sonia-
dc.contributor.authorWard, Stephen A.-
dc.contributor.authorMoore, David A. J.-
dc.date.accessioned2019-02-15T14:14:03Z-
dc.date.available2019-11-08T06:10:17Z-
dc.date.issued2018-11-08-
dc.identifier.issn0305-7453-
dc.identifier.urihttp://hdl.handle.net/2445/128328-
dc.description.abstractBackground: Poor response to TB therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharmacokinetic parameters can be affected by comorbidities or the interaction of drugs with food. Objectives: This study aimed to determine the effect of food intake upon pharmacokinetics of rifampicin and isoniazid in a Peruvian population with TB. Methods: Rifampicin and isoniazid levels were analysed at 2, 4 and 6 h after drug intake in both fasting and non-fasting states using LC-MS methods. Results: Sixty patients participated in the study. The median rifampicin Cmax and AUC0–6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P = 0.054) and 28.64 versus 24.31 mg·h/L (P = 0.002). There was a statistically significant delay overall of non-fasting Tmax compared with the fasting state Tmax (P = 0.005). In the multivariate analysis, besides the effect of fasting, Cmax for females was 20% higher than for males (P = 0.03). Concerning isoniazid, there were significant differences in the Cmax during non-fasting (median = 3.51 mg/L) compared with fasting (4.54 mg/L). The isoniazid dose received had an effect upon the isoniazid levels (1.26, P = 0.038). In the multivariate analysis, isoniazid exposure during fasting was found to be 14% higher than during non-fasting (CI = 1.02–1.28, P < 0.001). Neither radiological extent of the disease nor consumption of food with drug intake nor pharmacokinetics of rifampicin or isoniazid was associated with a poorer treatment outcome. Conclusions: Rifampicin in particular and isoniazid pharmacokinetics were significantly affected by the intake of the drug with food between and within individuals.ca
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengca
dc.publisherOxford University Pressca
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/ 10.1093/jac/dky444-
dc.relation.ispartofJournal of Antimicrobial Chemotherapy, 2019, vol. 74, num. 2, p. 416–424-
dc.relation.urihttp://dx.doi.org/ 10.1093/jac/dky444-
dc.rights(c) Oxford University Press, 2019-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationTuberculosi-
dc.subject.classificationFarmacocinètica-
dc.subject.otherTuberculosis-
dc.subject.otherPharmacokinetics-
dc.titleIntra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazidca
dc.typeinfo:eu-repo/semantics/articleca
dc.date.updated2019-02-14T15:18:18Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
Requena-Mendez_A_J_Antimicrob_Chemother_2018.pdf235.86 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.